Evidence map›Paper›PMID 41698047›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Nanotherapeutic Macrophage-Neuro Reprogramming Through Immunometabolic Crosstalk Mitigates Sepsis-Induced Lung Injury and Neurologic Damage.

Wenhui Wang, Yongrui Hai, Xintong Lu, Ye Chen, Bingjie Zhang, Renming Fan, Jiarui Dou, Jiaxin Yan, Shuo Fu, Wen Zhang and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenhui WangLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Yongrui HaiLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Xintong LuLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Ye ChenLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Bingjie ZhangLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Renming FanLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Jiarui DouLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Jiaxin YanLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.
Shuo FuInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.
Wen ZhangInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.
Junke SongInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.
Gaofei WeiLaboratory of Cellular Metabolism and Precision Therapeutics, School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, P. R. China.ORCID https://orcid.org/0000-0001-7180-7176

Funding

CAMS Innovation Fund for Medical Sciences 2022-I2M-1-015Innovation Foundation for Doctor Dissertation of Northwestern Polytechnical University ZX2025005National Natural Science Foundation of China 22577101National Natural Science Foundation of China 82173682National Natural Science Foundation of China 82374074Shenzhen Science and Technology Program JCYJ20250604183359078
6 · The paper itself

Abstract

Sepsis remains a leading cause of mortality in intensive care units, with its associated organ dysfunction primarily driven by uncontrolled inflammation and neuroimmune dysregulation. Among affected organs, the lung is particularly vulnerable, with injury involving both immune-mediated tissue damage and inflammation-induced neuronal impairment. Yet, whether coordinated targeting of immune and neural compartments can achieve synergistic and durable therapeutic benefits remains unknown. Here, we report a rationally engineered, dual-functional, enzyme-responsive nanoplatform (SJNPs) that co-delivers the glutamate production inhibitor JHU083 and the neuroprotective spermine (Spm) to reprogram macrophage-neuron immunometabolic interactions. SJNPs suppressed pro-inflammatory, M1-associated macrophage activation while promoting M2 polarization, which in turn drove robust secretion of the neurotrophic factor nerve growth factor (NGF) and preserved pulmonary neuronal integrity. Mechanistically, inhibition of glutamate metabolism reprogrammed macrophage polarization and activated NGF-mediated neurotrophic signaling, establishing NGF as a key mediator linking immune modulation to neural protection. In murine sepsis models, SJNPs attenuated systemic cytokine storms, mitigated alveolar damage, alleviated neurological injury, and improved survival. This study identifies macrophage-neuron immunometabolic crosstalk as a previously underexplored therapeutic target for septic lung injury characterized by neuronal damage, and establishes metabolic reprogramming of macrophages as a promising strategy for integrated immunomodulatory and neuroprotective therapy in sepsis.

Indexed as

Lung InjuryMacrophagesNeuronsSepsisAnimalsDisease Models, AnimalHumansMaleMetabolic ReprogrammingMiceMice, Inbred C57BLlung injurymacrophage‐neuro reprogrammingnanotherapyneuronal repairsepsis

Identifiers

PMID41698047
PMCPMC13116209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.